Back to News
Market Impact: 0.25
Bayer Moves To Expand KERENDIA Into Chronic Kidney Disease Without Diabetes
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The U.S. FDA accepted Bayer’s supplemental New Drug Application for KERENDIA, which seeks approval to treat adults with chronic kidney disease without diabetes. Acceptance allows the application to proceed through FDA review; it is not an approval.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
BAYN0.45
More News
- Roche Gets FDA Approval for Another Label Expansion of Tecentriq
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- Why is the Chinese stock market missing the AI rally
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- ‘Piece by piece’: Trump administration vows to dismantle the International Criminal Court with sweeping new sanctions